Carissa Tedeschi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carissa Tedeschi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alex Rock
Massachusetts General Hospital
1 shared publication - Alyssa R. Letourneau
Massachusetts General Hospital
1 shared publication - Cecilia Li
Massachusetts General Hospital
1 shared publication - Eric Gillett
Department of Pharmacy, Brigham and Women's Hospital , Boston, Massachusetts
1 shared publication - Jack Zhang
Department of Pharmaceutical Services, West Virginia University Hospitals , Morgantown, West Virginia
1 shared publication Jessica Johnson
Department of Medicine, Section of Infectious Diseases, West Virginia University , Morgantown, West Virginia
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Outcomes of early oral antibiotic transition for the treatment of uncomplicated enterococcal bacteremia
Objective: To compare clinical outcomes in adults with uncomplicated enterococcal bacteremia treated with intravenous (IV) therapy alone versus an early oral (PO) transition and evaluate treatment characteristics and safety outcomes. Design: Retrospective cohort study between January 1, 2021, and August 1, 2024. The primary outcome was clinical cure at 90 days after antibiotic completion. Secondary outcomes included treatment failure, infection-related readmission, hospital length of stay (HLOS), and 90-day mortality. Setting: Massachusetts General Hospital and Brigham and Women’s Hospital, two tertiary care centers in Boston, MA. Patients: Adult patients with at least one positive blood culture with Enterococcus spp. Patients were excluded if they had polymicrobial or persistent bacteremia, invasive infection, incomplete source control, died before completing therapy, or received fewer than 7 days of antibiotics. Results: 209 patients were included, of which 119 received IV therapy alone and 90 underwent early PO transition. Gastrointestinal (41.6%) and genitourinary (32.1%) sources were most common, and 86 patients (41.1%) had immunocompromising conditions. Clinical cure was similar between the IV and early PO transition groups (73.9% vs 82.2%; P = .156), with no significant differences in secondary and safety outcomes. HLOS was significantly shorter in the early PO transition group (9 days vs 20 days; P < .001). Conclusion: Early PO transition appears to be a safe and effective strategy for uncomplicated enterococcal bacteremia and was associated with reduced HLOS.
- 15 June 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Open AccessOutcomes of early oral antibiotic transition for the treatment of uncomplicated enterococcal bacteremia
Objective: To compare clinical outcomes in adults with uncomplicated enterococcal bacteremia treated with intravenous (IV) therapy alone versus an early oral (PO) transition and evaluate treatment characteristics and safety outcomes. Design: Retrospective cohort study between January 1, 2021, and August 1, 2024. The primary outcome was clinical cure at 90 days after antibiotic completion. Secondary outcomes included treatment failure, infection-related readmission, hospital length of stay (HLOS), and 90-day mortality. Setting: Massachusetts General Hospital and Brigham and Women’s Hospital, two tertiary care centers in Boston, MA. Patients: Adult patients with at least one positive blood culture with Enterococcus spp. Patients were excluded if they had polymicrobial or persistent bacteremia, invasive infection, incomplete source control, died before completing therapy, or received fewer than 7 days of antibiotics. Results: 209 patients were included, of which 119 received IV therapy alone and 90 underwent early PO transition. Gastrointestinal (41.6%) and genitourinary (32.1%) sources were most common, and 86 patients (41.1%) had immunocompromising conditions. Clinical cure was similar between the IV and early PO transition groups (73.9% vs 82.2%; P = .156), with no significant differences in secondary and safety outcomes. HLOS was significantly shorter in the early PO transition group (9 days vs 20 days; P < .001). Conclusion: Early PO transition appears to be a safe and effective strategy for uncomplicated enterococcal bacteremia and was associated with reduced HLOS.
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Bridging the Gap: Optimizing OPAT Transitions to Skilled Nursing Facilities
We evaluated patients discharged to skilled nursing facilities for outpatient parenteral antimicrobial therapy (OPAT). Among 89 patients, discharge medication errors and OPAT-related interventions were common, including laboratory monitoring, therapeutic adjustments, and adverse event management; 32 patients (36%) experienced at least 1 documented discharge medication error, with a total of 44 errors identified across the cohort. These findings highlight transition-of-care vulnerabilities and underscore the importance of structured OPAT oversight to improve patient safety.
- 3 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Open AccessBridging the Gap: Optimizing OPAT Transitions to Skilled Nursing Facilities
We evaluated patients discharged to skilled nursing facilities for outpatient parenteral antimicrobial therapy (OPAT). Among 89 patients, discharge medication errors and OPAT-related interventions were common, including laboratory monitoring, therapeutic adjustments, and adverse event management; 32 patients (36%) experienced at least 1 documented discharge medication error, with a total of 44 errors identified across the cohort. These findings highlight transition-of-care vulnerabilities and underscore the importance of structured OPAT oversight to improve patient safety.